Recent advances in regulatory T cell therapy of autoimmunity, graft rejection and cancer

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 4, Issue 3, 2010, Pages 231-243

  Dunne, Pádraic J ^a   Fletcher, Jean M ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Antibody therapy; Ex vivo expansion; NTreg; Regulatory T cells (Treg); TGF cancer; Th3; Tr1

Indexed keywords

ALPHA INTERMEDIN; CD137 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD39 ANTIGEN; CD40 ANTIGEN; CD52 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACLIZUMAB; DENILEUKIN DIFTITOX; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; L SELECTIN; MONOCLONAL ANTIBODY; PLACEBO; RAPAMYCIN; RECOMBINANT INTERLEUKIN 2; RETINOIC ACID; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; TGN 1412; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UC 10 4F10; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADOPTIVE IMMUNOTHERAPY; ALLERGIC ENCEPHALITIS; ALLERGIC ENCEPHALOMYELITIS; AMNESIA; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; BLOOD CELL; CANCER IMMUNOTHERAPY; CD25+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL ISOLATION; CLINICAL TRIAL; COCULTURE; COLITIS; CROHN DISEASE; CUTANEOUS T CELL LYMPHOMA; CYTOKINE PRODUCTION; CYTOKINE STORM; DENDRITIC CELL; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG INDUCED HEADACHE; EFFECTOR CELL; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMODYNAMIC INSTABILITY; HEMODYNAMICS; HUMAN; IMMATURE DENDRITIC CELL; IMMUNOLOGICAL TOLERANCE; KIDNEY INJURY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MELANOMA; METASTASIS INHIBITION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PARTIAL AMNESIA; PATENT; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYCLONAL REGULATORY T LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; RESPIRATORY DISTRESS SYNDROME; SIDE EFFECT; SKIN ALLOGRAFT; SKIN TRANSPLANTATION; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE RECEPTOR GENE; T LYMPHOCYTE SUBPOPULATION; TH3 CELL; THYMUS; UMBILICAL CORD BLOOD; UMBILICAL CORD BLOOD CELL; UVEORETINITIS; VIRAL GENE DELIVERY SYSTEM; VOMITING;

EID: 78649382906     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221310793564182     Document Type: Article

References (110)

1. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155(3): 1151-64.
2. Hori S, Sakaguchi S. Foxp3: A critical regulator of the development and function of regulatory T cells. Microbes Infect 2004; 6(8): 745-51.
3. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells. Nat Immunol 2003; 4(4): 330-6.
4. Wildin RS, Smyk-Pearson S, Filipovich AH. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet 2002; 39(8): 537-45.
5. Liston A, Rudensky AY. Thymic development and peripheral homeostasis of regulatory T cells. Curr Opin Immunol 2007; 19(2): 176-85.
6. Akbar AN, Vukmanovic-Stejic M, Taams LS, Macallan DC. The dynamic co-evolution of memory and regulatory CD4+ T cells in the periphery. Nat Rev Immunol 2007; 7(3): 231-7.
7. Lohr J, Knoechel B, Abbas AK. Regulatory T cells in the periphery. Immunol Rev 2006; 212: 149-62.
8. Sakaguchi S. The origin of FOXP3-expressing CD4+ regulatory T cells: Thymus or periphery. J Clin Invest 2003; 112(9): 1310-2.
9. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+ CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198(12): 1875-86.
10. Tran DQ, Ramsey H, Shevach EM. Induction of FOXP3 expression in naive human CD4+FOXP3- T cells by T cell receptor stimulation is TGF{beta}-dependent but does not confer a regulatory phenotype. Blood 2007; 110(8): 2983-90.
11. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 2004; 172(9): 5149-53.
12. Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, von Boehmer H. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 2005; 6(12): 1219-27.
13. Walker MR, Carson BD, Nepom GT, Ziegler SF, Buckner JH. De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+CD25- cells. Proc Natl Acad Sci USA 2005; 102(11): 4103-8.
14. Chai JG, Bartok I, Chandler P, Vendetti S, Antoniou A, Dyson J, et al. Anergic T cells act as suppressor cells in vitro and in vivo. Eur J Immunol 1999; 29(2): 686-92.
15. Taams LS, van Rensen AJ, Poelen MC, van Els CA, Besseling AC, Wagenaar JP, et al. Anergic T cells actively suppress T cell responses via the antigen-presenting cell. Eur J Immunol 1998; 28(9): 2902-12.
16. Roncador G, Brown PJ, Maestre L, Hue S, Martinez-Torrecuadrada JL, Ling KL, et al. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol 2005; 35(6): 1681-91.
17. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204(6): 1257-65.
18. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: Hydrolysis of extracellular ATP and immune suppression. Blood 2007; 110(4): 1225-32.
19. Fletcher JM, Lonergan R, Costelloe L, Kinsella K, Moran B, O'Farrelly C, et al. CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J Immunol 2009; 183(11): 7602-10.
20. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med.2006; 203(7): 1701-11.
21. Beriou G, Costantino CM, Ashley CW, Yang L, Kuchroo VK, Baecher-Allan C, et al. IL-17 producing human peripheral regulatory T cells retain suppressive function. Blood 2009; 113(18): 4240-9.
22. Voo KS, Wang YH, Santori FR, Boggiano C, Arima K, Bover L, et al. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci USA 2009; 106(12): 4793-8.
23. Sakaguchi S. Regulatory T cells in the past and for the future. Eur J Immunol 2008; 38(4): 901-37.
24. Garin MI, Chu CC, Golshayan D, Cernuda-Morollon E, Wait R, Lechler RI. Galectin-1: A key effector of regulation mediated by CD4+CD25+ T cells. Blood 2007; 109(5): 2058-65.
25. Miyara M, Sakaguchi S. Natural regulatory T cells: Mechanisms of suppression. Trends Mol Med 2007; 13(3): 108-16.
26. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006; 212: 28-50.
27. Mills KH, McGuirk P. Antigen-specific regulatory T cells--their induction and role in infection. Semin Immunol 2004; 16(2): 107-17.
28. Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev 2001; 182: 207-14.
29. Mills KH. Regulatory T cells: Friend or foe in immunity to infection? Nat Rev Immunol 2004; 4(11): 841-55.
30. Levings MK, Sangregorio R, Sartirana C, Moschin AL, Battaglia M, Orban PC, et al. Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells. J Exp Med 2002; 196(10): 1335-46.
31. Earle KE, Tang Q, Zhou X, Liu W, Zhu S, Bonyhadi ML, et al. In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation. Clin Immunol 2005; 115(1): 3-9.
32. Battaglia, M.M., Roncarolo, M.G. Method for expanding CD4+ CD25+ T regulatory cells. US0279826 (2008).
33. Bluestone, J.A.S.F., Tang, Q., Masteller, E. Regulatory T cells suppress autoimmunity. US7722862 (2010).
34. Li R, Ruttinger D, Si LS, Wang YL. Analysis of the immunological microenvironment at the tumor site in patients with non-small cell lung cancer. Langenbecks Arch Surg 2003; 388(6): 406-12.
35. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005; 105(12): 4743-8.
36. Basu S, Golovina T, Mikheeva T, June CH, Riley JL. Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. J Immunol 2008; 180(9): 5794-8.
37. Golovina TN, Mikheeva T, Suhoski MM, Aqui NA, Tai VC, Shan X, et al. CD28 costimulation is essential for human T regulatory expansion and function. J Immunol 2008; 181(4): 2855-68.
38. Blazar, B., June, C., Godfrey, W.R., Carroll, R.G., Levine, B., Riley, J.L., Taylor, P. Regulatory T cells and their use in immunotherapy and suppression of autoimmune responses. US7651855 (2010).
39. Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, et al. in vitro expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004; 199(11): 1455-65.
40. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al. Cytokine storm in a phase 1 trial of the anti- CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355(10): 1018-28.
41. Elpek KG, Yolcu ES, Franke DD, Lacelle C, Schabowsky RH, Shirwan H. Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling. J Immunol 2007; 179(11): 7295-304.
42. McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M, et al. CD4(+)CD25(+) immunoregulatory T cells: Gene expression analysis reveals a functional role for the glucocorticoidinduced TNF receptor. Immunity 2002; 16(2): 311-23.
43. Shirwan, H. Methods and compositions for expanding T regulatory cells. US0172947 (2007).
44. Hippen KL, Harker-Murray P, Porter SB, Merkel SC, Londer A, Taylor DK, et al. Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigenpresenting cells. Blood 2008; 112(7): 2847-57.
45. Wang Z, Hong J, Sun W, Xu G, Li N, Chen X, et al. Role of IFNgamma in induction of Foxp3 and conversion of CD4+ CD25- T cells to CD4+ Tregs. J Clin Invest 2006; 116(9): 2434-41.
46. Manoury-Schwartz B, Chiocchia G, Bessis N, Abehsira-Amar O, Batteux F, Muller S, et al. High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. J Immunol 1997; 158(11): 5501-6.
47. Ferber IA, Brocke S, Taylor-Edwards C, Ridgway W, Dinisco C, Steinman L, et al. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 1996; 156(1): 5-7.
48. Markees TG, Phillips NE, Gordon EJ, Noelle RJ, Shultz LD, Mordes JP, et al. Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4. J Clin Invest 1998; 101(11): 2446-55.
49. Feng G, Gao W, Strom TB, Oukka M, Francis RS, Wood KJ, et al. Exogenous IFN-gamma ex vivo shapes the alloreactive T-cell repertoire by inhibition of Th17 responses and generation of functional Foxp3+ regulatory T cells. Eur J Immunol 2008; 38(9): 2512-27.
50. Feng, G., Wood, K.J., Bushell, A. Production and use of regulatory T cells. US0162334 (2009).
51. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006; 24(2): 179-89.
52. Zheng SG, Wang J, Horwitz DA. Cutting edge: Foxp3+ CD4+CD25+ regulatory T cells induced by IL-2 and TGF-beta are resistant to Th17 conversion by IL-6. J Immunol 2008; 180(11): 7112-6.
53. Horwitz, D.A. Method to prevent graft rejection using TGF-beta to induce T suppressor cells. US6759035 (2001).
54. Aricha R, Feferman T, Fuchs S, Souroujon MC. Ex vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravis. J Immunol 2008; 180(4): 2132-9.
55. Lohr J, Knoechel B, Wang JJ, Villarino AV, Abbas AK. Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease. J Exp Med 2006; 203(13): 2785-91.
56. DiPaolo RJ, Brinster C, Davidson TS, Andersson J, Glass D, Shevach EM. Autoantigen-specific TGFbeta-induced Foxp3+ regulatory T cells prevent autoimmunity by inhibiting dendritic cells from activating autoreactive T cells. J Immunol 2007; 179(7): 4685-93.
57. Selvaraj RK, Geiger TL. Mitigation of experimental allergic encephalomyelitis by TGF-beta induced Foxp3+ regulatory T lymphocytes through the induction of anergy and infectious tolerance. J Immunol 2008; 180(5): 2830-8.
58. Zheng SG, Wang JH, Koss MN, Quismorio F, Jr, Gray JD, Horwitz DA. CD4+ and CD8+ regulatory T cells generated ex vivo with IL- 2 and TGF-beta suppress a stimulatory graft-versus-host disease with a lupus-like syndrome. J Immunol 2004; 172(3): 1531-9.
59. Coombes JL, Siddiqui KRR, Arancibia-Carcamo CV, Hall J, Sun C-M, Belkaid Y, et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-{beta}- and retinoic acid-dependent mechanism. J Exp Med 2007; 204(8): 1757-64.
60. Mucida D, Park Y, Kim G, Turovskaya O, Scott I, Kronenberg M, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007; 317(5835): 256-60.
61. Cheroutre, H., Park, Y., De Sousa, M., Vicente-Suarez, I. Regulatory T cells and methods for making and using same. US0136470 (2009).
62. Wang G, Zhong A, Wang S, Dong N, Sun Z, Xia J. Retinoic acid attenuates acute heart rejection by increasing regulatory T cell and repressing differentiation of Th17 cell in the presence of TGF-beta. Transpl Int 2010; [Epub ahead of print]
63. Zeng M, Guinet E, Nouri-Shirazi M. Comparative analysis of dendritic cells and anti-CD3/CD28 expanded regulatory T cells for application in transplantation. Transpl Immunol 2009; 22(1-2): 82-92.
64. Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389(6652): 737-42.
65. Allan SE, Broady R, Gregori S, Himmel ME, Locke N, Roncarolo MG, et al. CD4+ T-regulatory cells: Toward therapy for human diseases. Immunol Rev 2008; 223: 391-421.
66. Battaglia M, Gregori S, Bacchetta R, Roncarolo M-G. Tr1 cells: From discovery to their clinical application. Semin Immunol 2006; 18(2): 120-7.
67. Brun V, Bastian H, Neveu V, Foussat A. Clinical grade production of IL-10 producing regulatory Tr1 lymphocytes for cell therapy of chronic inflammatory diseases. Int Immunopharmacol 2009; 9(5): 609-13.
68. Foussat, A., Belmonte, N. Tr1 cells, mesenchymal stem cells and uses thereof. WO050282 (2009).
69. Wright GP, Notley CA, Xue SA, Bendle GM, Holler A, Schumacher TN, et al. Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc Natl Acad Sci USA 2009; 106(45): 19078-83.
70. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000; 192(9): 1213-22.
71. Dhodapkar MV, Steinman RM. Antigen-bearing immature dendritic cells induce peptide-specific CD8+ regulatory T cells in vivo in humans. Blood 2002; 100(1): 174-7.
72. Dhodapkar, M.V., Steinman, R.M., Bhardwaj, N. Use of immature dendritic cells to silence antigen-specific CD8+ T cell function. US0175890 (2009).
73. Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, Daley J, et al. CD40-activated human B cells: An alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 1997; 100(11): 2757-65.
74. Tu W, Lau YL, Zheng J, Liu Y, Chan PL, Mao H, et al. Efficient generation of human alloantigen-specific CD4+ regulatory T cells from naive precursors by CD40-activated B cells. Blood 2008; 112(6): 2554-62.
75. Tu, W., Lau, Y.L., Lewis, D.B. Method to induce and expand therapeutic alloantigenspecific human regulatory T cells in largescale. US0324557 (2009).
76. Zheng J, Liu Y, Lau YL, Tu W. CD40-activated B cells are more potent than immature dendritic cells to induce and expand CD4(+) regulatory T cells. Cell Mol Immunol 2010; 7(1): 44-50.
77. Watanabe T, Masuyama J, Sohma Y, Inazawa H, Horie K, Kojima K, et al. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. Clin Immunol 2006; 120(3): 247-59.
78. Rowan W, Tite J, Topley P, Brett SJ. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 1998; 95(3): 427-36.
79. Pulaski HL, Spahlinger G, Silva IA, McLean K, Kueck AS, Reynolds RK, et al. Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. J Transl Med 2009; 7: 49.
80. Masuyama, J., Watanabe, T., Soma, Y., Yamaguchi, Y. Method of inducing differentiation and proliferating regulatory T cell by anti- CD52 antibody and medicinal composition thereof. US0228351 (2006).
81. Ichiyama T, Sakai T, Catania A, Barsh GS, Furukawa S, Lipton JM. Systemically administered alpha-melanocyte-stimulating peptides inhibit NF-kappaB activation in experimental brain inflammation. Brain Res 1999; 836(1-2): 31-7.
82. Lipton JM, Zhao H, Ichiyama T, Barsh GS, Catania A. Mechanisms of antiinflammatory action of alpha-MSH peptides. In vivo and in vitro evidence. Ann N Y Acad Sci 1999; 885: 173-82.
83. Namba K, Kitaichi N, Nishida T, Taylor AW. Induction of regulatory T cells by the immunomodulating cytokines alphamelanocyte- stimulating hormone and transforming growth factorbeta2. J Leukoc Biol 2002; 72(5): 946-52.
84. Taylor, A., Nashida, T. Activation of regulatory T cells by alphamelanocyte stimulating hormone. US0090724 (2002).
85. Ng TF, Kitaichi N, Taylor AW. In vitro generated autoimmune regulatory T cells enhance intravitreous allogeneic retinal graft survival. Invest Ophthalmol Vis Sci 2007; 48(11): 5112-7.
86. Park YH, Koo SK, Kim Y, Kim HM, Joe IY, Park CS, et al. Effect of in vitro expanded CD4(+)CD25(+)Foxp3(+) regulatory T cell therapy combined with lymphodepletion in murine skin allotransplantation. Clin Immunol 2009; 135(1): 43-54.
87. Koenecke C, Czeloth N, Bubke A, Schmitz S, Kissenpfennig A, Malissen B, et al. Alloantigen-specific de novo-induced Foxp3+ Treg revert in vivo and do not protect from experimental GVHD. Eur J Immunol 2009; 39(11): 3091-6.
88. Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007; 19(4): 345-54.
89. Gagliani N, Jofra T, Stabilini A, Valle A, Atkinson M, Roncarolo MG, et al. Antigen-specific dependence of Tr1-cell therapy in preclinical models of islet transplant. Diabetes 2009; 59(2): 433-9.
90. Gagliani N, Ferraro A, Roncarolo MG, Battaglia M. Autoimmune diabetic patients undergoing allogeneic islet transplantation: Are we ready for a regulatory T-cell therapy? Immunol Lett 2009; 127(1): 1-7.
91. Monti P, Scirpoli M, Maffi P, Piemonti L, Secchi A, Bonifacio E, et al. Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells. Diabetes 2008; 57(9): 2341-7.
92. Luhder F, Huang Y, Dennehy KM, Guntermann C, Muller I, Winkler E, et al. Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J Exp Med 2003; 197(8): 955-66.
93. Beyersdorf N, Gaupp S, Balbach K, Schmidt J, Toyka KV, Lin CH, et al. Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med 2005; 202(3): 445-55.
94. Antony PA, Restifo NP. CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother 2005; 28(2): 120-8.
95. Chen X, Oppenheim JJ, Winkler-Pickett RT, Ortaldo JR, Howard OM. Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP3(+)CD4(+)CD25(+) T regulatory cells in vivo and enhances their capacity to suppress EAE. Eur J Immunol 2006; 36(8): 2139-49.
96. Wilson MS, Pesce JT, Ramalingam TR, Thompson RW, Cheever A, Wynn TA. Suppression of murine allergic airway disease by IL- 2: anti-IL-2 monoclonal antibody-induced regulatory T cells. J Immunol 2008; 181(10): 6942-54.
97. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006; 311(5769): 1924-7.
98. Wilson SB, Kent SC, Patton KT, Orban T, Jackson RA, Exley M, et al. Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature 1998; 391(6663): 177-81.
99. Ribas A, Hanson DC, Noe DA, Millham R, Guyot DJ, Bernstein SH, et al. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 2007; 12(7): 873-83.
100. Coquerelle C, Oldenhove G, Acolty V, Denoeud J, Vansanten G, Verdebout JM, et al. Anti-CTLA-4 treatment induces IL-10- producing ICOS+ regulatory T cells displaying IDO-dependent anti-inflammatory properties in a mouse model of colitis. Gut 2009; 58(10): 1363-73.
101. Matsushita N, Pilon-Thomas SA, Martin LM, Riker AI. Comparative methodologies of regulatory T cell depletion in a murine melanoma model. J Immunol Methods 2008; 333(1-2): 167-79.
102. Curtin JF, Candolfi M, Fakhouri TM, Liu C, Alden A, Edwards M, et al. Treg depletion inhibits efficacy of cancer immunotherapy: Implications for clinical trials. PLoS One 2008; 3(4): e1983.
103. Jacob JB, Kong YC, Nalbantoglu I, Snower DP, Wei WZ. Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity. J Immunol 2009; 182(9): 5873-81.
104. Bieganowska K, Hollsberg P, Buckle GJ, Lim DG, Greten TF, Schneck J, et al. Direct analysis of viral-specific CD8+ T cells with soluble HLA-A2/Tax11-19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathy. J Immunology 1999; 162(3): 1765-71.
105. Rasku MA, Clem AL, Telang S, Taft B, Gettings K, Gragg H, et al. Transient T cell depletion causes regression of melanoma metastases. J Transl Med 2008; 6: 12.
106. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999; 59(13): 3128-33.
107. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: A common basis between tumor immunity and autoimmunity. J Immunol 1999; 163(10): 5211-8.
108. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001; 194(6): 823-32.
109. Frankel AE, Surendranathan A, Black JH, White A, Ganjoo K, Cripe LD. Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia. Cancer 2006; 106(10): 2158-64.
110. Berger CL, Tigelaar R, Cohen J, Mariwalla K, Trinh J, Wang N, et al. Cutaneous T-cell lymphoma: Malignant proliferation of Tregulatory cells. Blood 2005; 105(4): 1640-7.